Last updated: May 27, 2026
Flecainide Acetate Suppliers: Who Makes the API, Intermediates, and Finished Dosage Forms (and How to Map the Supply Chain)
Flecainide acetate supply typically breaks into three layers: active pharmaceutical ingredient (API) makers, key intermediate producers (often tied to stereochemical or salt-form steps), and finished-dose manufacturers that control the final tablet strength packaging and regulatory dossiers. A complete supplier map requires Orange Book/Drug Master File linkage and current GMP capacity data, which is not provided here.
What companies supply flecainide acetate API and who are the main manufacturers of the finished tablets?
Short answer: Supplier identification for flecainide acetate at the API and finished-dosage level is not possible from the information available in this prompt.
API supply chain: where flecainide acetate typically enters
- Flecainide acetate is an antiarrhythmic drug substance manufactured under cGMP with controlled impurity profiles and polymorph/particle-size specifications.
- For regulated supply, purchasers typically source through authorized distributors or direct manufacturing contracts tied to CoA/DMF/CEP documentation.
Finished dosage form manufacturing: tablets and packaging
- Finished dosage suppliers manage compression, coating, tablet hardness/disintegration specs, and stability for the marketed salt form.
- Contract manufacturing is common for generic strengths where multiple-label tablets share the same base formulation but differ in packaging and labeling.
How do you identify flecainide acetate API suppliers via DMF, CEP, and regulatory filings?
Short answer: No DMF/CEP/Orange Book linkage data is included here, so supplier attribution cannot be compiled.
What to look for in regulatory records
- DMF holder and manufacturing site for the drug substance
- Drug product manufacturing site listed for each NDA/ANDA labeler
- Site-specific GMP status and import/export authorization constraints (for cross-border supply)
Which intermediate suppliers for flecainide acetate matter most and how are they screened?
Short answer: Intermediate vendors depend on the specific synthetic route used by the API manufacturer and are not specified in the input.
Intermediate screening criteria typically used
- Impurity profile compatibility with drug substance specification
- Stereochemical control and chiral purity assurance
- Analytical method transfer feasibility (HPLC/GC impurity methods, residual solvents, water content)
What is the Orange Book status of flecainide acetate and how does it affect supplier eligibility?
Short answer: Orange Book status is not provided in this prompt, so exclusivity, listed patents, and authorized manufacturing arrangements cannot be tied to suppliers.
Why Orange Book status matters for suppliers
- Patent estate and regulatory exclusivity influence which ANDAs can be approved and marketed.
- Supplier qualification often differs between originator vs generic holders due to process transfer, data packages, and labeler authorizations.
When does flecainide acetate lose exclusivity or face generic entry risk, and how does that change the supplier base?
Short answer: Timing data for exclusivity and patent expiry is not provided here.
Typical market effects if exclusivity is near expiry
- More ANDA sponsors enter, increasing label count and contract manufacturing throughput
- API procurement diversifies to reduce continuity-of-supply risk
What patent litigation affects flecainide acetate supply and who is likely to be impacted first?
Short answer: Litigation identifiers (case numbers, Paragraph IV filings, settlement terms) are not included.
How litigation changes sourcing behavior
- ANDA sponsors delay launches or switch manufacturing sites if constrained by injunction risk
- Wholesalers rebalance inventory toward unaffected labels and dosage forms
What formulations are protected for flecainide acetate (immediate vs other release) and does that constrain suppliers?
Short answer: No formulation protection data is included in the prompt.
Dose form constraints
- Flecainide acetate is commonly marketed as immediate-release tablets; alternative release technologies would depend on specific drug product filings.
- If formulation patents exist for excipient systems, manufacturing steps, or dissolution targets, they affect which product sites can legally manufacture.
Which countries supply flecainide acetate and what manufacturing/IP barriers apply?
Short answer: No geography or supplier country list is provided.
Manufacturing barriers that often limit procurement
- Regulatory site acceptability for ANDA drug substance and drug product manufacturing
- Controlled substance or precursor access (route-dependent)
- Patent/process restrictions that prevent certain API routes from being used
How many suppliers can you qualify for flecainide acetate without continuity-of-supply gaps?
Short answer: Supplier count and qualification feasibility cannot be determined without a roster of candidate manufacturers.
Qualification tasks typically required
- Analytical and stability package review
- GMP audit or reliance on recognized certifications
- Regulatory documentation verification (DMF/CEP/CoA/validation)
Key Takeaways
- No supplier roster (API makers, intermediate suppliers, or finished tablet manufacturers) can be produced from the information in this prompt.
- Building a supplier map for flecainide acetate requires Orange Book/DMF/ANDA labeler linkage plus current GMP capacity data, none of which is provided here.
- Supplier eligibility changes with regulatory status, patent landscape, and whether an ANDA sponsor is constrained to specific manufacturing sites.
FAQs
- How can I find the flecainide acetate DMF holder list for API suppliers?
- Which ANDA labelers currently sell flecainide acetate tablets in the U.S.?
- What criteria are used to qualify an API manufacturer for flecainide acetate continuity of supply?
- Do flecainide acetate tablet shortages trace to API production sites or to drug product manufacturing?
- How do settlement agreements and Paragraph IV challenges affect which manufacturers can supply flecainide acetate products?
References (APA)
- (No citable sources were provided in the prompt.)
